Prot #CAIN457AUS01: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compa

  • Gordon, Kenneth B (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/5/14 → 6/30/16

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CAIN457AUS01)